Active Biotech AB – Interim report January – March 2019

First quarter in brief

  • Active Biotech’s partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA (“naptumumab”) in combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II study
  • On 1 February 2019, Active Biotech received an indicative, non-binding bid of SEK 275 M for the company’s property from the real estate company Estea AB. The indicative bid is conditional on the customary due diligence process and Estea securing financing. Active Biotech’s Board takes a positive view of the bid
  • Active Biotech entered into an agreement regarding the sale of the company’s property Forskaren 1 in Lund, Sweden, with a newly formed investor collective led by the real estate company Estea AB
  • The US Patent Office (USPTO) approved the patent application regarding tasquinimod for the treatment of acute leukemia in the US

Events after the end of the period

  • In accordance with the Board’s proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company’s property to Estea AB
  • Active Biotech completed the sale of the property, Forskaren 1, to Estea AB on April 5, 2019. The purchase price amounts to SEK 275 M, which corresponds to the property’s carrying amount. The transaction generated a liquidity injection of approximately SEK 70 M

Financial summary




2019 2018


Net sales




Operating loss




Loss after tax




Loss per share (SEK)




Cash and cash equivalents (at close of the period)




For further information, please contact:

  Helén Tuvesson, VD
  Tfn 046-19 21 56


  Hans Kolam, CFO
  Tfn 046-19 20 44

Active Biotech AB
( 556223-9227)
Box 724, 220 07 Lund
Tfn 046-19 20 00

Read the full report here.